Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Retained Earnings: 2019-2024

Historic Retained Earnings for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to -$275.5 million.

  • Pharming Group N.V's Retained Earnings rose 0.54% to -$276.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$276.9 million, marking a year-over-year increase of 0.54%. This contributed to the annual value of -$275.5 million for FY2024, which is 3.86% down from last year.
  • According to the latest figures from FY2024, Pharming Group N.V's Retained Earnings is -$275.5 million, which was down 3.86% from -$265.3 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Retained Earnings registered a high of $24.6 million during FY2020, and its lowest value of -$275.5 million during FY2024.
  • Over the past 3 years, Pharming Group N.V's median Retained Earnings value was -$265.3 million (recorded in 2023), while the average stood at -$183.2 million.
  • As far as peak fluctuations go, Pharming Group N.V's Retained Earnings surged by 107.22% in 2020, and later slumped by 2,936.08% in 2023.
  • Yearly analysis of 5 years shows Pharming Group N.V's Retained Earnings stood at $24.6 million in 2020, then slumped by 86.19% to $3.4 million in 2021, then plummeted by 356.97% to -$8.7 million in 2022, then slumped by 2,936.08% to -$265.3 million in 2023, then declined by 3.86% to -$275.5 million in 2024.